iNCOVACC (ChAd36-SARS-CoV-S COVID-19 vaccine (recombinant)) / Bharat Biotech, Washington University School of Medicine in St. Louis - LARVOL DELTA

A review of currently licensed mucosal COVID-19 vaccines. (PubMed, Vaccine) - "This highlights the importance of expanded research in this field. In this review, we aim to summarize what is known about these currently licensed vaccines, with an emphasis on the key findings obtained in both preclinical and clinical studies."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Effect of heterologous intranasal iNCOVACC® vaccination as a booster to two-dose intramuscular Covid-19 vaccination series: a randomized phase 3 clinical trial. (PubMed, Commun Med (Lond)) - P3 | "These findings demonstrate that impact of booster across different cohorts is governed by infection status of the individual and geographical diversity, thus necessitating large cohorts, well distributed studies before Covid-19 booster effects are interpreted."

Journal • P3 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Mucosal immunization with ChAd-SARS-CoV-2-S prevents sequential transmission of SARS-CoV-2 to unvaccinated hamsters. (PubMed, Sci Adv) - "In contrast, sequential transmission occurred after systemic immunization with the mRNA vaccine. Thus, immunization with a mucosal COVID-19 vaccine protects against cycles of respiratory transmission of SARS-CoV-2 and can potentially limit the community spread of the virus."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Mucosal vaccine-induced cross-reactive CD8+ T cells protect against SARS-CoV-2 XBB.1.5 respiratory tract infection. (PubMed, Nat Immunol) - "A nasally delivered chimpanzee adenoviral-vectored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (ChAd-SARS-CoV-2-S) is currently used in India (iNCOVACC)...However, depletion of memory CD8+ T cells before XBB.1.5 challenge resulted in loss of protection against upper and lower respiratory tract infection. Thus, nasally delivered vaccines stimulate mucosal immunity against emerging SARS-CoV-2 strains, and cross-reactive memory CD8+ T cells mediate protection against lung infection by antigenically distant strains in the setting of low serum levels of cross-reactive neutralizing antibodies."

Journal • Infectious Disease • Novel Coronavirus Disease • Otorhinolaryngology • Respiratory Diseases • CD8

Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin). (PubMed, NPJ Vaccines) - P3 | "Both vaccines were well tolerated. Overall reported solicited reactions were 6.9% and 25.5% and unsolicited reactions were 1.2% and 3.1% in BBV154 and Covaxin participants respectively."

Journal • P3 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

"hopeful for #covaxin or #incovacc" (@dvmknnth)

"And hopefully @BARDA will consider supporting @Ocugen for both covaxin and Incovacc. We shouldn’t limit ourselves." (@Dfwmb123)

"#COVAXIN #INCOVACC @NIHDirector @HHSGov @DrCaliff_FDA @CDCDirector @AshishKJha46 @elonmusk @RickABright @WHCOVIDResponse #bharatbiotech #ocugen #OCU500" (@Diego48979433)

Novel Coronavirus Disease

"Let me guess, PFE or Moderna must not have a next gen nasal vaccines yet #BuyingTime Meanwhile #iNCOVACC #Covaxin are ready" (@doc_holliday50)

Clinical

"#COVAXIN #INCOVACC @NIHDirector @HHSGov @DrCaliff_FDA @CDCDirector @AshishKJha46 @elonmusk @WHCOVIDResponse #bharatbiotech #ocugen #OCU500" (@Diego48979433)

Novel Coronavirus Disease

"#COVAXIN #INCOVACC @NIHDirector @HHSGov @DrCaliff_FDA @CDCDirector @AshishKJha46 @elonmusk @WHCOVIDResponse #bharatbiotech #ocugen #OCU500" (@Diego48979433)

Novel Coronavirus Disease

"#COVAXIN #INCOVACC @NIHDirector @HHSGov @DrCaliff_FDA @CDCDirector @AshishKJha46 @elonmusk @WHCOVIDResponse #bharatbiotech #ocugen" (@Diego48979433)

Novel Coronavirus Disease

"#COVAXIN #INCOVACC @NIHDirector @HHSGov @DrCaliff_FDA @CDCDirector @AshishKJha46 @elonmusk @WHCOVIDResponse #bharatbiotech #ocugen" (@Diego48979433)

Novel Coronavirus Disease

"#iNCOVACC and #Covaxin" (@doc_holliday50)

"#COVAXIN #INCOVACC @NIHDirector @HHSGov @DrCaliff_FDA @CDCDirector @AshishKJha46 @elonmusk @WHCOVIDResponse #bharatbiotech #ocugen" (@Diego48979433)

Novel Coronavirus Disease

"#covaxin #incovacc" (@NathanR91334798)

"@Ocugen just pay the fee like @moderna_tx and @pfizer if not will never see covaxin or incovacc in the United States @NIH @US_FDA @CDCgov = PAY TO PLAY." (@NathanR91334798)

"@NIHDirector @HHSGov @DrCaliff_FDA @CDCDirector @AshishKJha46 @elonmusk @WHCOVIDResponse #covaxin #incovacc #bharatbiotech #ocugen" (@Diego48979433)

Novel Coronavirus Disease

"Approve Covaxin and incovacc. They may be the one way out of this mess." (@Dfwmb123)

"#IchooseCOVAXIN #INCOVACC #Ocugen #BharatBiotech #IRefusemRNA" (@CraigGordon8)

"@NIHDirector @HHSGov @DrCaliff_FDA @CDCDirector @AshishKJha46 @elonmusk @WHCOVIDResponse #covaxin #incovacc #bharatbiotech #ocugen" (@Diego48979433)

Novel Coronavirus Disease

"@NIHDirector @HHSGov @DrCaliff_FDA @CDCDirector @AshishKJha46 @WHCOVIDResponse #covaxin #incovacc #bharatbiotech #ocugen" (@Diego48979433)

Novel Coronavirus Disease

"@NIHDirector @HHSGov @DrCaliff_FDA @CDCDirector @AshishKJha46 @elonmusk @WHCOVIDResponse #covaxin #incovacc #bharatbiotech #ocugen" (@Diego48979433)

Novel Coronavirus Disease

"Let’s get covaxin and incovacc avail world." (@Dfwmb123)

"@US_FDA @FDA_Drug_Info @DrCaliff_FDA #COVAXIN and #INCOVACC would be great for the people @Ocugen @BharatBiotech" (@nrbarile)

Clinical